Drugs / Aroeira
Aroeira
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04069286 | Mar 2025 → Jul 2026 overdue | dyspepsia | Infan Industria Quimica Farmaceutica Nacional | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aroeira | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04069286 ↗ |
| Known as | oral mastic | “Our primary objective will be "Compare the effectiveness of oral mastic (Schinus terebinthifolia Raddi) versus omeprazole in relieving complete description of the symptoms of...” NCT04069286 ↗ |
| Known as | Schinus Terebinthifolia Raddi | “Active Group oral Aroeira (Schinus Terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks” NCT04069286 ↗ |
| Route | Oral | “oral Aroeira (Schinus terebinthifolia Raddi)” NCT04069286 ↗ |